Outcomes remain poor for many patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), particularly those with high-risk disease. Frontline rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) does not provide disease control in a substantial proportion of patients, highlighting a significant unmet need for high-risk patients.

The phase 3 frontMIND study was designed to address this gap by testing whether the addition of tafasitamab, an anti-CD19 monoclonal antibody, and lenalidomide to R-CHOP could improve disease control in a high-risk population that included patients with DLBCL or high-grade B-cell lymphoma (International Prognostic Index [IPI], 3-5, or age-adjusted IPI, 2-3, for patients aged ≤60 years) and an ECOG Performance Status of 0 to 2.

In this global double-blind study, at the primary analysis (data cutoff, Oct 20, 2025), 899 patients were randomized to tafasitamab-lenalidomide-R-CHOP (n=448) or R-CHOP alone (n=451). Progression-free survival (PFS) was the primary endpoint, with event-free survival (EFS), overall survival (OS), overall response rates (ORR), and safety as key secondary measures.

Patients were stratified according to risk group. 57.8% of patients in the tafasitamab-lenalidomide-R-CHOP arm and 54.1% in the R-CHOP arm were high-intermediate risk and 41.5% in the tafasitamab-lenalidomide-R-CHOP arm and 44.8% in the R-CHOP arm were high-risk. At a median follow-up of 35.2 months, tafasitamab-lenalidomide-R-CHOP significantly improved PFS compared with R-CHOP in the overall population, corresponding to a hazard ratio (HR) of 0.75 (95% CI, 0.59-0.96; P=.019). Similarly, in patients with centrally confirmed lymphoma subtype (n=773), tafasitamab-lenalidomide-R-CHOP conferred a PFS benefit (HR, 0.68; 95% CI, 0.52-0.88), and the 24-month PFS rate was 72.7% versus 62.2% with tafasitamab-lenalidomide-R-CHOP vs R-CHOP.

Improvement in PFS was also reported across both major cell-of-origin subtypes, activated B-cell–like and germinal center B-cell–like, suggesting that the effect was not confined to a single biological subgroup. Tafasitamab-lenalidomide-R-CHOP was also associated with significantly improved EFS versus R CHOP (HR, 0.79; P=.026). ORR was comparable (80.4% vs 76.1%) and complete response rates were identical between the 2 arms (65.2% in both arms). At the time of analysis, OS did not differ significantly between the groups (HR, 0.85; P=.270).

Safety was generally consistent with the expected profiles of the study drugs and the R-CHOP backbone, although treatment-emergent adverse events (AEs) of grade ≥3 were more common with tafasitamab-lenalidomide-R-CHOP than with R-CHOP alone (86.7% vs 76.1%). Discontinuations due to AEs and treatment-emergent deaths were also higher in the tafasitamab plus lenalidomide and R-CHOP arm than R-CHOP alone, although overall deaths were numerically lower compared with R-CHOP alone (18.5% vs 21.7%).

Together, these data suggest that adding tafasitamab and lenalidomide to R-CHOP can improve frontline disease control in high-risk DLBCL without introducing unexpected safety concerns, although longer follow-up will be important, particularly for OS. The data indicate improved disease control in this high-risk population with an associated increase in higher-grade AEs, within the context of a manageable safety profile. The results support further consideration of this regimen as a potential frontline option for patients with high-risk DLBCL or high-grade B-cell lymphoma.

Source: Lenz G, et al. frontMIND: phase 3 study of tafasitamab plus lenalidomide and R-CHOP for patients with newly diagnosed diffuse large B-cell lymphoma. Presented at: ASCO Annual Meeting. May 29-June 2, 2026; Chicago, IL. Abstract LBA7000.